Clinical Trials · NCT01679080

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

TerminatedPhase 2Teriparatide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
University of Aarhus
Enrollment
9
Start date
Nov 2012
Locations
3 sites, Denmark
Primary endpoint
Bone Mineral Density (BMD)
View Teriparatide compound reference